Findings for Frontline Dato-DXd From TROPION-Breast02 in Immunotherapy-Ineligible TNBC

The TROPION-Breast02 trial investigates datopotamab deruxtecan (Dato-DXd), another TROP-2–directed ADC, as a potential frontline option for patients with immunotherapy-ineligible TNBC. Panelists review results showing promising efficacy with manageable toxicity, including mucositis and stomatitis as notable side effects. Dato-DXd demonstrated durable responses and progression-free survival comparable to or better than standard chemotherapy. The panel underscores the growing importance of ADCs in expanding options for patients who cannot receive immunotherapy and notes that differences in linker technology and payload may influence outcomes compared to other ADCs like sacituzumab. They anticipate further data to refine its optimal use in frontline and combination settings.